Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Mineralys Therapeutics has raised $500.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.
Mineralys Therapeutics's investors include RA Capital Management, Adams Street Partners, Andera Partners, Samsara BioCapital, TCG Crossover.
Mineralys Therapeutics is headquartered in Radnor, United States.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Mineralys Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mineralys Therapeutics — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/mineralys-therapeutics. Accessed August 6, 2026.
VCBacked. (2026). Mineralys Therapeutics — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/mineralys-therapeutics
{{cite web |title=Mineralys Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mineralys-therapeutics |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated